Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Kobo Biotech Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
4 users have voted
Option Chain
Analyzes market sentiment, predicts Kobo Biotech Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
-
Kobo Biotech - Corporate Insolvency Resolution Process (CIRP)-Invitation of Resolution Plan
Key fundamentals
Evaluate the intrinsic value of Kobo Biotech Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 6.7808 | 11.8596 | 18.2871 | 101.0605 | 110.8906 |
| Liabilities | 6.7808 | 11.8596 | 18.2871 | 101.0605 | 110.8906 |
| Equity | 23.825 | 23.825 | 23.825 | 23.825 | 23.825 |
| Gross Profit | -0.8726 | -1.4965 | -10.5017 | -2.7894 | -2.6077 |
| Net Profit | -4.9288 | -5.5534 | -15.2259 | -19.2312 | -21.0061 |
| Cash From Operating Activities | 0.2036 | 0.8746 | 93.7569 | 13.6714 | 14.4756 |
| NPM(%) | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.8726 | 1.4965 | 10.5017 | 2.7894 | 2.6077 |
| ROE(%) | 3.7 | 4.17 | 11.45 | 14.46 | 15.8 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Kobo Biotech Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Nitta Gelatin India Ltd | 870.75 | -2.89 | 9.68 | 3.12 | 924.57 | 0.92 |
| Sharda Cropchem Ltd | 817.00 | -5.46 | 16.31 | 31.04 | 337.37 | 1.10 |
| Ram Minerals and Chemicals Ltd | 0.49 | 0.00 | 49.00 | 70.79 | -0.09 | 0.00 |
| Amines and Plasticizers Ltd | 217.10 | -0.87 | 29.68 | 18.93 | 372.61 | 0.23 |
Company Info
YEAR EVENTS 1993 - The Company was incorporated on August 03, as Avon Organics Limited. It obtained certificate of commencement of business on July 5, 1994, promoted by Mr. P.R. Agarwal, Mr. Rajesh Agarwal and Dr. G.S. Sidhu. - The company proposes to manufacture Diketene and derivatives - Mono Methyl Acetoacetamide (MMA) and Methyl Aceto Acetate (MAA). Diketene is the mother chemical and is in itself not sold. 1994 - The Company has entered into a Tripartite Agreement dated 12th October 1994, for which the Department of Industrial Development, Secretariat of Industrial Approvals, Ministry of Industry, has given permission vide their letter FC.II No:90(93)/4/ILF/93 dated April 2nd, 1993, with Shanghai Machinery & Equipment Import & Export Corporation (SMEC), on behalf of Shanghai Peng Pu Chemical Works (SPCW) for technology transfer and with Xytel Technologies Partnership, U S A for the co-ordination and transfer of technology (between the Company and SMEC). 2000 -Avon Organics Ltd. the Hyderabad-based pharmaceutical company into the manufacture of chemical intermediates, proposes to venture into the area of bio-technology. 2002 -Avon Organics has entered into a long-term international contract for supply of one of its products with a Global MNC. 2004 -Avon Organics is introducing two high value added intermediates in its Diketene Division. 2007 -Avon Organics has designed a E-mail ID for Investors Complaints as cs_1@avonorganicsltd.com 2010 -Avon Organics has recommended a dividend of Re. 1/- i.e. 10% per equity share of Rs. 10/- each 2011 -Avon Organics has recommended a dividend of Re. 1/- i.e. 10% per equity share of Rs 10/- each 2013 - Mr. Rajendra Kaimal has been appointed as Non-Executive Director on the Board of Directors of the Company 2014 - Mr. Jignesh Patel is appointed as a Company Secretary and Compliance Officer of the Company - Dr. Sunil Pitroda has been appointed as an Additional Director in the category of Non-Executive Independent Director on the Board of the Company. 2015 -The Company has changed its name from Avon Organics Ltd to Avon Lifesciences Ltd. 2020 -Company name has changed to Kobo Biotech Ltd. from Avon Lifesciences Ltd..
YEAR EVENTS 1993 - The Company was incorporated on August 03, as Avon Organics Limited. It obtained certificate of commencement of business on July 5, 1994, promoted by Mr. P.R. Agarwal, Mr. Rajesh Agarwal and Dr. G.S. Sidhu. - The company proposes to manufacture Diketene and derivatives - Mono Methyl Acetoacetamide (MMA) and Methyl Aceto Acetate (MAA). Diketene is the mother chemical and is in itself not sold. 1994 - The Company has entered into a Tripartite Agreement dated 12th October 1994, for which the Department of Industrial Development, Secretariat of Industrial Approvals, Ministry of Industry, has given permission vide their letter FC.II No:90(93)/4/ILF/93 dated April 2nd, 1993, with Shanghai Machinery & Equipment Import & Export Corporation (SMEC), on behalf of Shanghai Peng Pu Chemical Works (SPCW) for technology transfer and with Xytel Technologies Partnership, U S A for the co-ordination and transfer of technology (between the Company and SMEC). 2000 -Avon Organics Ltd. the Hyderabad-based pharmaceutical company into the manufacture of chemical intermediates, proposes to venture into the area of bio-technology. 2002 -Avon Organics has entered into a long-term international contract for supply of one of its products with a Global MNC. 2004 -Avon Organics is introducing two high value added intermediates in its Diketene Division. 2007 -Avon Organics has designed a E-mail ID for Investors Complaints as cs_1@avonorganicsltd.com 2010 -Avon Organics has recommended a dividend of Re. 1/- i.e. 10% per equity share of Rs. 10/- each 2011 -Avon Organics has recommended a dividend of Re. 1/- i.e. 10% per equity share of Rs 10/- each 2013 - Mr. Rajendra Kaimal has been appointed as Non-Executive Director on the Board of Directors of the Company 2014 - Mr. Jignesh Patel is appointed as a Company Secretary and Compliance Officer of the Company - Dr. Sunil Pitroda has been appointed as an Additional Director in the category of Non-Executive Independent Director on the Board of the Company. 2015 -The Company has changed its name from Avon Organics Ltd to Avon Lifesciences Ltd. 2020 -Company name has changed to Kobo Biotech Ltd. from Avon Lifesciences Ltd..
Read More
Parent Organisation
Kobo Biotech Ltd.
Founded
03/08/1993
Managing Director
NSE Symbol
FAQ
The current price of Kobo Biotech Ltd is
The 52-week high for Kobo Biotech Ltd is
The market capitalization of Kobo Biotech Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Kobo Biotech Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Kobo Biotech Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Kobo Biotech Ltd shares.
The CEO of Kobo Biotech Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
